Chimeric Antigen Receptor T Cell Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

Chimeric Antigen Receptor T Cell Stocks Recent News

Date Stock Title
May 7 JANX Janux Therapeutics GAAP EPS of -$0.30 beats by $0.03
May 7 CRBU Caribou Bioscience GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M
May 7 CRBU Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
May 7 CRBU Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 7 JANX Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 7 TSVT 2seventy bio Q1 2024 Earnings Preview
May 7 ACET Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
May 6 CARM Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 3 TSVT 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 3 PSTX Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
May 2 JANX Janux Therapeutics gains amid renewed takeover speculation
May 2 CARM Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
May 2 CARM Carisma Therapeutics names Eugene Kennedy as chief medical officer
May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2 CARM Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
May 2 PSTX Xyphos and Poseida to develop allogeneic cell therapies for cancer
May 1 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
May 1 PSTX Poseida gains on cell therapy pact with Astellas
Chimeric Antigen Receptor T Cell

Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

Browse All Tags